What experiences have myMPNteam members shared about switching from hydroxyurea to Jakafi due to low platelets?
It's understandable to want to hear from others who've made this switch. While specific member experiences about this exact transition aren't detailed in available information, here's what's known about Jakafi Show Full Answer
What experiences have myMPNteam members shared about switching from hydroxyurea to Jakafi due to low platelets?
It's understandable to want to hear from others who've made this switch. While specific member experiences about this exact transition aren't detailed in available information, here's what's known about Jakafi that may help:
About Jakafi (ruxolitinib):
Jakafi is a JAK inhibitor that blocks proteins signaling cells to grow. It's FDA-approved for certain types of myelofibrosis and for polycythemia vera that hasn't responded to hydroxyurea or when someone can't tolerate it.
Important considerations:
- Like hydroxyurea, Jakafi can cause low levels of red and white blood cells, as well as platelets
- It carries a higher risk of infections in general
- It may cause dormant infections (like herpes zoster, hepatitis, or tuberculosis) to reactivate
When Jakafi is typically used:
According to hematologists, Jakafi shouldn't necessarily be the first medication tried for every patient. For PV patients specifically, hydroxyurea generally needs to be tried first since Jakafi isn't approved as a first-line treatment for PV. However, when hydroxyurea isn't working or causes intolerable side effects, Jakafi can be an excellent option.
Your doctor will monitor you closely with regular blood work during treatment. Stay in close communication about any symptoms or side effects you experience.
April 7
Join
Your Privacy Choices
